SURMODICS INC: directors' dealings · United States · SEC (Form 4)

About SURMODICS INC

Surmodics Inc. (ticker: SRDX) is a U.S.-based healthcare company listed on the NASDAQ in the United States, headquartered in Eden Prairie, Minnesota. For French-speaking investors, it is best viewed as a specialized medtech and diagnostics-enabling business rather than a broad hospital or pharma supplier. Its model sits at the intersection of high-performance medical-device coatings, device development and manufacturing services, and chemical/biological components used in in vitro diagnostic assays. That mix gives the company an innovation-led profile, with revenue influenced by product qualification cycles, regulatory milestones, and customer adoption rather than mass-market demand. ([surmodics.com](https://www.surmodics.com/technical-expertise?utm_source=openai)) Surmodics traces its roots back more than 40 years. The company highlights a long heritage in surface technology, including the development of a drug-delivery coating for the first drug-eluting stent. That legacy remains central to the story: Surmodics has built a reputation for hydrophilic, hemocompatible, and drug-delivery coatings used by leading medical-device manufacturers. Over time, it expanded beyond coatings into differentiated whole-product solutions, including advanced balloon catheter design and production capabilities in both the U.S. and Ireland. This makes the company more than a materials supplier; it is also a development and manufacturing partner for complex catheter-based systems. ([surmodics.com](https://www.surmodics.com/about-surmodics?utm_source=openai)) Operationally, Surmodics is organized around two core commercial areas. The Medical Device business covers performance coatings, surface technologies, and contract development/manufacturing for vascular intervention and other intravascular devices. The In Vitro Diagnostics business supplies critical chemical and biological components such as protein stabilizers, substrates, and reagents for immunoassay tests and microarrays. Management positions the company as a bridge between concept and commercialization, serving both large strategic medtech customers and smaller innovators that need technical support, prototyping, and scale-up. ([sec.gov](https://www.sec.gov/Archives/edgar/data/924717/000095017024129020/srdx-20240930.htm?utm_source=openai)) From a competitive standpoint, Surmodics occupies a niche but strategically important position in the medtech value chain. Its differentiation rests on technical depth, application expertise, and intellectual property rather than commodity pricing. The company states that its surface-technology leadership is built on rigorous testing and that its facilities are certified to ISO quality standards. Geographically, the company is primarily U.S.-anchored, with corporate and technical operations in Eden Prairie, Minnesota, and a European operating footprint in Ireland. Its customer relationships are global, spanning coronary, peripheral, neurovascular, and structural-heart applications, as well as diagnostic and research markets. ([surmodics.com](https://www.surmodics.com/technical-expertise?utm_source=openai)) A major recent development has been the proposed acquisition by GTCR announced in 2024 and later challenged by U.S. antitrust authorities in 2025. Surmodics disclosed in SEC filings that completion remains subject to closing conditions and litigation-related uncertainty. At the same time, the company continues to emphasize product and clinical momentum around platforms such as SurVeil DCB, Sundance DCB, and Pounce, with recent registry and trial-related communications supporting its technology narrative. For investors, SRDX therefore combines a specialized healthcare innovation story with M&A optionality and meaningful event risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/924717/000095017025105477/srdx-20250630.htm?utm_source=openai))